ACE2 and COVID-19: Moreover, patients who have been receiving systemic pharmacotherapy with angiotensin-converting enzyme (ACE) inhibitors, as SARS-CoV-2 revealed a certain predilection to angiotensin-converting enzyme 2 (ACE2) receptors, can be potentially more susceptible severe respiratory tract complications resulting from COVID-19 [16,17].